Keryx Biopharmaceuticals PE Ratio
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
About Price to Earnings Ratio
The price to earnings ratio (PE Ratio) is the measure of the share price relative to the annual net income earned by the firm per share. PE ratio shows current investor demand for a company share. A high PE ratio generally indicates increased demand because investors anticipate earnings growth in the future. The PE ratio has units of years, which can be interpreted as the number of years of earnings to pay back purchase price.
PE ratio is often referred to as the "multiple" because it demonstrates how much an investor is willing to pay for one dollar of earnings. PE Ratios are sometimes calculated using estimations of next year's earnings per share in the denominator. When this happens, it is usually noted.
Learn More
You may also be interested in these KERX related companies
KERX News
Keryx to Present at 14th Annual BIO CEO & Investor Conference; $KERX http://stks.co/2LF8
about 2 days ago by keryxbiopharma
about 2 days ago by keryxbiopharma
Keryx Biopharmaceuticals to Present at 14th Annual BIO CEO and Investor Conference
Feb 08, 8:30AM PR Newswire
Feb 08, 8:30AM PR Newswire
January's bullish run continues this month for $KERX 3.63+0.12, lots of upside with analysts' average consensus price target of 10.29
about 9 days ago by silverjet2
about 9 days ago by silverjet2
Congrats to those who sold in morning, sorry if you remain bag holder $KERX very weak now $$
about 11 days ago by peterumble
about 11 days ago by peterumble
@peterumble Good call on $kerx selling off! Foolish to buy on this dip?
about 11 days ago by ChasinCheddar
about 11 days ago by ChasinCheddar
My brother told me about $kerx last week, didn't jump in. Wish i had, congrats longs!
about 11 days ago by ChasinCheddar
about 11 days ago by ChasinCheddar
$kerx was a steal down here. i added to my macros. have a 14 buck price tgt on it gang
about 11 days ago by Proptr4d3r
about 11 days ago by Proptr4d3r
Inovio Pharmaceuticals and Keryx Biopharmaceuticals Benefit From Strengthening Biotech Sector
Jan 25, 8:20AM Marketwire
Jan 25, 8:20AM Marketwire
Keryx Biopharmaceuticals to Present at JP Morgan's 30th Annual Healthcare Conference
Jan 04, 8:30AM PR Newswire
Jan 04, 8:30AM PR Newswire
A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)
Dec 14, 9:00AM Marketwire
Dec 14, 9:00AM Marketwire
Keryx Biopharma (KERX) Reports Strong Phase 2 Data for Perifosine w/ Sorafenib in Certain HL Patients
Dec 13, 8:28AM Street Insider
Dec 13, 8:28AM Street Insider
Keryx Biopharmaceuticals announces presentation of study for perifosine
Dec 13, 8:21AM theflyonthewall.com
Dec 13, 8:21AM theflyonthewall.com
Oppenheimer Maintains Outperform Rating and $8 PT on KERYX Biopharmaceuticals
Nov 15, 8:30AM Benzinga
Nov 15, 8:30AM Benzinga
Europe Situation Forecasts Change -- Report Highlights NetApp Inc. and Keryx Biopharmaceuticals
Nov 11, 9:00AM Marketwire
Nov 11, 9:00AM Marketwire
Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 11, 8:30AM PR Newswire
Nov 11, 8:30AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| KERX | 3.20 | -0.10 | -3.03% | 223.04M |
| CBI | 43.42 | -0.23 | -0.53% | 4.28B |
| MLNX | 36.66 | -0.12 | -0.33% | 1.44B |
| CV | 35.17 | 0.06 | 0.17% | 471.98M |
| BIDZ | 0.55 | 0.02 | 3.75% | 10.66M |
| CM | 76.73 | -0.65 | -0.84% | 30.62B |
| ASUR | 6.77 | 0.02 | 0.30% | 20.92M |
| NWSA | 19.18 | -0.04 | -0.18% | 33.02B |
| DOX | 30.35 | 0.04 | 0.13% | 5.23B |
| BCSI | 25.80 | 0.03 | 0.12% | 1.09B |
